BCR and neoplasm: Subcutaneous injection of these BCR/ABL-trapped cells into immunodeficient mice led to a strong inhibition of tumour growth, resulting in a 90% reduction in tumour burden relative to control tumours (Cas9 + donor and parental), 23 days post-injection.